<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072539</url>
  </required_header>
  <id_info>
    <org_study_id>3074X1-4527</org_study_id>
    <secondary_id>B1811040</secondary_id>
    <nct_id>NCT01072539</nct_id>
  </id_info>
  <brief_title>Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment</brief_title>
  <official_title>A Post-marketing Surveillance (Pms) Study Of Safety And Effectiveness In Patients With Tigecycline Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to identify any changes on the safety profile of
      adverse events and serious adverse events. And the secondary objective is to evaluate
      clinical response in the clinically evaluable population at test-of cure (TOC) or at the end
      of treatment (EOT) assessment, and microbiologic response at the subject level, if available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to the conduct of this study, the investigator will explain the study objective, etc to
      prospective subjects on the basis of &quot;explanatory material.&quot; The informed consent will be
      obtained in written form by each subject voluntarily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), and Unexpected AEs/ADRs</measure>
    <time_frame>From the time of the participant's first dosing in the observational period as per study design through and including 28 calendar days after the last administration of the study drug within the observational period.</time_frame>
    <description>All AEs reported after start of administration of Tygacil were considered as on treatment and summarized. All AEs, except for those with causal relationship to the study drug assessed as &quot;unlikely&quot;, were considered as ADRs. Unexpected AEs/ADRs were classified by medical review with reference to the approved local product document and confirmed by Pfizer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events by Baseline and Treatment Characteristics</measure>
    <time_frame>From the time of the participant's first dosing in the observational period as per study design through and including 28 calendar days after the last administration of the study drug within the observational period.</time_frame>
    <description>Baseline and treatment characteristics included: prospectively/retrospectively collected data, geriatric status (&lt;65 years or &gt;=65 years), age categories, sex, duration of disease, infection site, severity of infection, general, present and past medical history, kidney disorder, liver disorder, total administration period of Tygacil, mean daily dose of Tygacil, past medication and therapy, and concomitant medications.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response of Cure or Improvement at the Test-of-Cure(TOC) or End-of-Treatment (EOT) Assessment</measure>
    <time_frame>At the TOC or EOT assessment</time_frame>
    <description>Participants whose clinical response was assessed as cure or improvement at the TOC or EOT assessment were considered as &quot;effective&quot; to the treatment of Tygacil .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response of Cure or Improvement at the TOC or EOT Assessment by Infection Site</measure>
    <time_frame>At the TOC or EOT assessment</time_frame>
    <description>Participants whose clinical response was assessed as cure or improvement at the TOC or EOT assessment were considered as &quot;effective&quot; to the treatment of Tygacil .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants by Microbiologic Response at the Participant Level (Prospective Study Phase)</measure>
    <time_frame>At the TOC or EOT assessment</time_frame>
    <description>Definitions: Eradication: None of the baseline isolates were present in a repeat culture taken from the original site of infection (documented) or a clinical response of cure precluded the availability of a specimen for culture (presumed). Persistence: Any baseline isolates were present in a repeat culture obtained from the original site of infection (documented) or culture data were not available for a participant with a clinical response of failure (presumed). Unevaluable: participants who died during therapy for non-infection-related reasons, died for any reason within 2 days after first administration of Tygacil, were lost to follow-up (ie, clinical response was not able to be assessed), or had no baseline isolates.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3172</enrollment>
  <condition>Complicated Skin and Skin Structure Infections</condition>
  <condition>Complicated Intra-abdominal Infections</condition>
  <condition>Community-Acquired Bacterial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Patients who have approved indications of Tygacil</arm_group_label>
    <description>Approved indications of Tygacil
-complicated intraabdominal infection, complicated skin and skin structure infection, community-acquired bacterial pneumonia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tigecycline</intervention_name>
    <description>As prescribed by physician in usual clinical practice</description>
    <arm_group_label>Patients who have approved indications of Tygacil</arm_group_label>
    <other_name>Tygacil</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        General Hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Evidence of a personally signed and dated informed consent document indicating that the
        subject (or a legal representative) has been informed of all pertinent aspects of the
        study. Subjects must meet all of the following inclusion criteria to be eligible for
        enrollment into the study :

        Adults 18 years of age or older, who have one of the followings:

          -  Complicated skin and skin structure infections

          -  Complicated intra-abdominal infections

          -  Community-acquired bacterial pneumonia

        Exclusion Criteria:

        Subjects presenting with any of the following will not be included in the study:

          -  Patients who have known hypersensitivity to tigecycline

          -  Patients with rare hereditary problems of galactose intolerance, the Lapp lactase
             deficiency, or glucose-galactose malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan-si</city>
        <state>Gyeongnam</state>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Namdong-gu</city>
        <state>Incheon</state>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonkwang University Hospital</name>
      <address>
        <city>Iksan-si</city>
        <state>Jeollabuk-do</state>
        <zip>573-250</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanil Medical Center</name>
      <address>
        <city>Dobong-Gu</city>
        <state>Seoul</state>
        <zip>132-033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Medical Center (Dong-A University Hospital)</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheongju St. Mary's Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <zip>363-568</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center (KUDMC)</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital (KNUH)</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu fatima hospital</name>
      <address>
        <city>Daegu</city>
        <zip>701-724</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center (DCUMC)</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju</city>
        <zip>690-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Wonju College of Medicine- Wonju Christian Hospital</name>
      <address>
        <city>Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University College of Medicine Severance Hospital Rheumatology Internal Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Medical Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>134-727</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>134-814</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, University of Ulsan</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>139-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center (HUMC) - Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>682-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3074X1-4527&amp;StudyName=Study%20Evaluating%20The%20Safety%20And%20Effectiveness%20In%20Subjects%20With%20Tigecycline%20Treatment</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <results_first_submitted>April 21, 2016</results_first_submitted>
  <results_first_submitted_qc>April 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2016</results_first_posted>
  <last_update_submitted>April 21, 2016</last_update_submitted>
  <last_update_submitted_qc>April 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infection</keyword>
  <keyword>Tygacil</keyword>
  <keyword>PMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tigecycline</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled between May 2010 and April 2015 from Korean health care centers.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tygacil</title>
          <description>Participants were administered Tygacil as part of routine practice. The use and dosage recommendations for Tygacil were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3169">Refer to the Safety Analysis Set. Data for completion were not collected.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Treated prior to the Site Initiation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: participants who received at least one dose of Tygacil and had related safety endpoints evaluated at least once.</population>
      <group_list>
        <group group_id="B1">
          <title>Tygacil</title>
          <description>Participants were administered Tygacil as part of routine practice. The use and dosage recommendations for Tygacil were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 to 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 to 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Infection Site</title>
          <description>cSSSI: Complicated skin and skin structure infection; cIAI: Complicated intra-abdominal infection; CAP: Community-acquired bacterial pneumonia.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>cSSSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cIAI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cIAI + cSSSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cIAI + CAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severity of Infection</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), and Unexpected AEs/ADRs</title>
        <description>All AEs reported after start of administration of Tygacil were considered as on treatment and summarized. All AEs, except for those with causal relationship to the study drug assessed as “unlikely”, were considered as ADRs. Unexpected AEs/ADRs were classified by medical review with reference to the approved local product document and confirmed by Pfizer.</description>
        <time_frame>From the time of the participant's first dosing in the observational period as per study design through and including 28 calendar days after the last administration of the study drug within the observational period.</time_frame>
        <population>Safety Anaysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Tygacil</title>
            <description>Participants were administered Tygacil as part of routine practice. The use and dosage recommendations for Tygacil were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs (SAEs)/Serious ADRs (SADRs), and Unexpected AEs/ADRs</title>
          <description>All AEs reported after start of administration of Tygacil were considered as on treatment and summarized. All AEs, except for those with causal relationship to the study drug assessed as “unlikely”, were considered as ADRs. Unexpected AEs/ADRs were classified by medical review with reference to the approved local product document and confirmed by Pfizer.</description>
          <population>Safety Anaysis Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADRs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SADRs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unexpected AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unexpected ADRs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response of Cure or Improvement at the Test-of-Cure(TOC) or End-of-Treatment (EOT) Assessment</title>
        <description>Participants whose clinical response was assessed as cure or improvement at the TOC or EOT assessment were considered as “effective” to the treatment of Tygacil .</description>
        <time_frame>At the TOC or EOT assessment</time_frame>
        <population>Effectiveness Analysis Set: Participants who received at least one dose of Tygacil and had related effectiveness endpoints evaluated at least.</population>
        <group_list>
          <group group_id="O1">
            <title>Tygacil</title>
            <description>Participants were administered Tygacil as part of routine practice. The use and dosage recommendations for Tygacil were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response of Cure or Improvement at the Test-of-Cure(TOC) or End-of-Treatment (EOT) Assessment</title>
          <description>Participants whose clinical response was assessed as cure or improvement at the TOC or EOT assessment were considered as “effective” to the treatment of Tygacil .</description>
          <population>Effectiveness Analysis Set: Participants who received at least one dose of Tygacil and had related effectiveness endpoints evaluated at least.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2545"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prospectively Collected Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.68" lower_limit="55.63" upper_limit="63.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retrospectively Collected Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.97" lower_limit="73.07" upper_limit="76.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.59" lower_limit="69.84" upper_limit="73.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response of Cure or Improvement at the TOC or EOT Assessment by Infection Site</title>
        <description>Participants whose clinical response was assessed as cure or improvement at the TOC or EOT assessment were considered as “effective” to the treatment of Tygacil .</description>
        <time_frame>At the TOC or EOT assessment</time_frame>
        <population>Effectiveness Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Tygacil</title>
            <description>Participants were administered Tygacil as part of routine practice. The use and dosage recommendations for Tygacil were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response of Cure or Improvement at the TOC or EOT Assessment by Infection Site</title>
          <description>Participants whose clinical response was assessed as cure or improvement at the TOC or EOT assessment were considered as “effective” to the treatment of Tygacil .</description>
          <population>Effectiveness Analysis Set.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2545"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infection Site: cSSSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.53" lower_limit="74.66" upper_limit="80.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection Site: cIAI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.52" lower_limit="69.28" upper_limit="73.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection Site: CAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.35" lower_limit="37.91" upper_limit="52.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection Site: cIAI + cSSSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection Site: cIAI + CAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00" lower_limit="0.00" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection Site: Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.59" lower_limit="69.84" upper_limit="73.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among subgroups of Infection Sites: cSSSI, cIAI, CAP, cIAI + cSSSI, and cIAI + CAP.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events by Baseline and Treatment Characteristics</title>
        <description>Baseline and treatment characteristics included: prospectively/retrospectively collected data, geriatric status (&lt;65 years or &gt;=65 years), age categories, sex, duration of disease, infection site, severity of infection, general, present and past medical history, kidney disorder, liver disorder, total administration period of Tygacil, mean daily dose of Tygacil, past medication and therapy, and concomitant medications.</description>
        <time_frame>From the time of the participant’s first dosing in the observational period as per study design through and including 28 calendar days after the last administration of the study drug within the observational period.</time_frame>
        <population>Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Tygacil</title>
            <description>Participants were administered Tygacil as part of routine practice. The use and dosage recommendations for Tygacil were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events by Baseline and Treatment Characteristics</title>
          <description>Baseline and treatment characteristics included: prospectively/retrospectively collected data, geriatric status (&lt;65 years or &gt;=65 years), age categories, sex, duration of disease, infection site, severity of infection, general, present and past medical history, kidney disorder, liver disorder, total administration period of Tygacil, mean daily dose of Tygacil, past medication and therapy, and concomitant medications.</description>
          <population>Safety Analysis Set.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prospectively Collected Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.15" lower_limit="30.73" upper_limit="37.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retrospectively Collected Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.62" lower_limit="30.76" upper_limit="34.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Geriatric: &lt;65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.98" lower_limit="28.84" upper_limit="33.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Geriatric: &gt;=65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.55" lower_limit="33.03" upper_limit="38.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age: &lt;30 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.16" lower_limit="22.15" upper_limit="38.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age: 40 to 49 Yeas</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.46" lower_limit="22.75" upper_limit="32.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age: 50 to 64 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.99" lower_limit="29.25" upper_limit="34.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age: &gt;=65 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.55" lower_limit="33.03" upper_limit="38.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex: Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.55" lower_limit="30.53" upper_limit="34.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex: Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.79" lower_limit="30.98" upper_limit="36.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Disease: &lt;3 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.88" lower_limit="31.15" upper_limit="34.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Disease: &gt;=3 Months and &lt;6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.63" lower_limit="27.43" upper_limit="39.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of Disease: &gt;=6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.20" lower_limit="20.28" upper_limit="44.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection Site: cSSSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.79" lower_limit="25.95" upper_limit="31.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection Site: cIAI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.87" lower_limit="32.76" upper_limit="36.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection Site: CAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.30" lower_limit="28.32" upper_limit="40.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection Site: cIAI + cSSSI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00" lower_limit="0.00" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection Site: cIAI + CAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00" lower_limit="0.00" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of Infection: Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.83" lower_limit="21.70" upper_limit="31.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of Infection: Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.27" lower_limit="25.35" upper_limit="29.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of Infection: Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.75" lower_limit="46.31" upper_limit="53.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Medical History: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.91" lower_limit="33.19" upper_limit="36.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Medical History: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.48" lower_limit="3.20" upper_limit="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Medical History (Present): Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.03" lower_limit="33.29" upper_limit="36.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Medical History (Present): No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.45" lower_limit="5.85" upper_limit="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Medical History (Past): Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.10" lower_limit="34.14" upper_limit="40.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Medical History (Past): No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.00" lower_limit="29.04" upper_limit="32.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney Disorder: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.86" lower_limit="42.89" upper_limit="50.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney Disorder: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.69" lower_limit="27.92" upper_limit="31.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Disorder: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.82" lower_limit="36.65" upper_limit="43.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Disorder: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.20" lower_limit="28.30" upper_limit="32.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Treatment Period of Tygacil: &lt;7 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.74" lower_limit="31.40" upper_limit="38.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Treatment Period of Tygacil: 7 to 14 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.94" lower_limit="27.39" upper_limit="32.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Treatment Period of Tygacil: &gt;14 Days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.99" lower_limit="32.23" upper_limit="37.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Daily Dose of Tygacil: &lt;50 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="100.00" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Daily Dose of Tygacil: 50 to &lt;100 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.92" lower_limit="36.50" upper_limit="43.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Daily Dose of Tygacil: 100 to &lt;200 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.57" lower_limit="28.72" upper_limit="32.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Daily Dose of Tygacil: &gt;=200 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" lower_limit="17.06" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past Medication and Therapy: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.48" lower_limit="31.77" upper_limit="35.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past Medication and Therapy: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.02" lower_limit="21.49" upper_limit="32.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant Medications: Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.77" lower_limit="32.09" upper_limit="35.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant Medications: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.06" lower_limit="8.04" upper_limit="20.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Geriatrc: &lt;65 Years Versus (VS) Geriatrc: &gt;=65 Years</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among Age categories: &lt;30 Years, 30 to 39 Years, 40 to 49 Years, 50 to 64 Years, and &gt;=65 Years.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0412</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Sex: Male VS Sex: Female</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4792</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparson among Duration of Disease categories: &lt;3 Months, &gt;=3 Months and &lt;6 Months, and &gt;=6 Months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9669</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among subgroups of infection site: cSSSI, cIAI, CAP, cIAI + cSSSI, and cIAI + CAP.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among severity of infection subgroups: Mild, Moderate, and Severe.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Satistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>General Medical History: Yes VS General Medical History: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>General Medical History (Present): Yes VS General Medical History (Present): No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>General Medical History (Past): Yes VS General Medical History (Past): No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Kidney Disorder: Yes VS Kidney Disorder: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Liver Disorder: Yes VS Liver Disorder: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among subgroups of Total Treatment Period of Tygacil: &lt;7 Days, 7 to 14 Days, and &gt;14 Days</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0153</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison among subgroups of Mean Daily Dose of Tygacil: &lt;50 mg, 50 to &lt;100 mg, 100 to &lt;200 mg, and &gt;=200 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level 0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Past Medication and Therapy: Yes VS Past Medication and Therapy: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0376</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Concomitant Medications: Yes VS Concomitant Medications: No</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant level: 0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants by Microbiologic Response at the Participant Level (Prospective Study Phase)</title>
        <description>Definitions: Eradication: None of the baseline isolates were present in a repeat culture taken from the original site of infection (documented) or a clinical response of cure precluded the availability of a specimen for culture (presumed). Persistence: Any baseline isolates were present in a repeat culture obtained from the original site of infection (documented) or culture data were not available for a participant with a clinical response of failure (presumed). Unevaluable: participants who died during therapy for non-infection-related reasons, died for any reason within 2 days after first administration of Tygacil, were lost to follow-up (ie, clinical response was not able to be assessed), or had no baseline isolates.</description>
        <time_frame>At the TOC or EOT assessment</time_frame>
        <population>Effectiveness Analysis Set from the prospective study phase; n refers to the total munber of participants who had evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tygacil</title>
            <description>Participants were administered Tygacil as part of routine practice. The use and dosage recommendations for Tygacil were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants by Microbiologic Response at the Participant Level (Prospective Study Phase)</title>
          <description>Definitions: Eradication: None of the baseline isolates were present in a repeat culture taken from the original site of infection (documented) or a clinical response of cure precluded the availability of a specimen for culture (presumed). Persistence: Any baseline isolates were present in a repeat culture obtained from the original site of infection (documented) or culture data were not available for a participant with a clinical response of failure (presumed). Unevaluable: participants who died during therapy for non-infection-related reasons, died for any reason within 2 days after first administration of Tygacil, were lost to follow-up (ie, clinical response was not able to be assessed), or had no baseline isolates.</description>
          <population>Effectiveness Analysis Set from the prospective study phase; n refers to the total munber of participants who had evaluable data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="563"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eradication (Documented or Presumed) (n=514)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistence (Documented or Presumed) (n=514)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unevaluable (n=514)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of the participant’s first dosing in the observational period as per study design through and including 28 calendar days after the last administration of the study drug within the observational period.</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tygacil</title>
          <description>Participants were administered Tygacil as part of routine practice. The use and dosage recommendations for Tygacil were based on the approved local product document and were adjusted solely according to medical and therapeutic necessity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>WHO-ART version 092</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="419" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Haemorrhage not otherwise specified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Marrow depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Fibrillation atrial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Fibrillation ventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Colitis pseudomembranous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Intestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation of disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Multiple organ failure</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Hepatocellular damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Serum glutamic oxaloacetic transaminase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Serum glutamic pyruvate transaminase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Infection aggravated</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Application site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoma small intestine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Leukaemia granulocytic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Melanoma malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Secondary carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Brain stem disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Carboxyhaemoglobinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Convulsions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Oedema cerebral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Renal failure chronic aggravated</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Renal function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Respiratory insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Stevens johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Amputation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Surgical intervention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis deep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>WHO-ART version 092</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="537" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Serum glutamic oxaloacetic transaminase increased</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="3169"/>
              </event>
              <event>
                <sub_title>Serum glutamic pyruvate transaminase increased</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Phosphatase alkaline increased</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="3169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

